Tipifarnib - Kura Oncology

Drug Profile

Tipifarnib - Kura Oncology

Alternative Names: NSC-702818; R-115777; Zarnestra

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen L.P.; Janssen-Cilag; Johnson & Johnson
  • Developer Emory University; H. Lee Moffitt Cancer Center and Research Institute; Janssen-Cilag; Johnson & Johnson; Kura Oncology; National Cancer Institute (USA); Samsung Medical Center; Spanish Lung Cancer Group; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Quinolones; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Chronic myelomonocytic leukaemia; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Peripheral T-cell lymphoma; Thyroid cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Preclinical Cutaneous T cell lymphoma
  • Discontinued Breast cancer; Glioblastoma; Pancreatic cancer

Most Recent Events

  • 23 May 2018 OncoDNA signs a screening agreement a with Kura Oncology to support patient enrolment for HRAS tipifarnib trial
  • 08 May 2018 Preclinical trials in Lung cancer in USA (unspecified route)
  • 03 May 2018 Kura Oncology has patent protection for tipifarnib for CXCL12-expressing Peripheral T-cell lymphoma (PTCL) or Acute myeloid leukaemia (AML) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top